Pediatric heart failure therapy with β-adrenoceptor antagonists

Pediatric Drugs

Volumn 10, Issue 2, 2008, Pages 125-134

  Foerster, Susan R ^a   Canter, Charles E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta adrenergic receptor antagonists, therapeutic use; Cardiomyopathy, treatment; Carvedilol, therapeutic use; Children; Heart failure, treatment; Metoprolol, therapeutic use; Phosphodiesterase inhibitors, therapeutic use

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENOXIMONE; INOTROPIC AGENT; LEVOSIMENDAN; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MILRINONE; NEBIVOLOL; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTAGLANDIN E1;

CARDIOGENIC SHOCK; CARDIOMYOPATHY; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEART FAILURE; HEART PROTECTION; HEART TRANSPLANTATION; HEART VENTRICLE CONTRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MUSCLE ATROPHY; PEDIATRICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUDDEN DEATH; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADRENERGIC BETA-ANTAGONISTS; CARDIOMYOPATHY, DILATED; CHILD; HEART FAILURE; HUMANS; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; VENTRICULAR DYSFUNCTION;

EID: 40949097007     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810020-00007     Document Type: Review

References (65)

1. Buchhorn R, Bartmus D, Siekmeyer W, et al. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am J Cardiol 1998 Jun; 81 (11): 1366-8
2. Packer M, Coats AJS, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure. Carvedilol Prospective Randomized Cumulative Survival study group. N Engl J Med 2001; 344 (22): 1651-8
3. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study group. Circulation 2002; 106: 2194-9
4. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003 Jul; 362: 7-13
5. Poole-Wilson PA. Commentary on the Carvedilol or Metoprolol European Trial (COMET). Am J Cardiol 2004; 93 (9 Suppl. 1): 40B-2B
6. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol study (CIBIS-II). Lancet 1999; 353: 9-13
7. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999; 353: 2001-7
8. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005 Feb; 26 (3): 215-25
9. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67
10. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138: 505-11
11. Giesler G, Lenihan DJ, Durand JB. The update on the rationale, use and selection of β-blockers in heart failure. Curr Opin Cardiol 2004; 19: 250-3
12. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2003; 63 (16): 1697-741
13. Foody JM, Farrell MH, Krumholz HM. ?-blocker therapy in heart failure. JAMA 2002 Feb; 287 (7): 883-9
14. Weber M. The role of the new β-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18: 169S-76S
15. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 2002; 21: 906-9
16. Shaddy RE, Curtin EL, Sower B, et al., for the Pediatric Randomized Carvedilol Trial in Children with Heart Failure study. The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design. Am Heart J 2002; 144: 383-9
17. Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999; 18: 269-74
18. Okafor CC, Perreault-Micale C, Hajjar RJ, et al. Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiol 2003 Jul 21; 3:6. Epub 2003 Jul 21 [online]. Available from URL: http://www.biomedcentral.com/1472-6793/3/6 [Accessed 2008 Jan 16]
19. Udelson JE. Ventricular remodeling in heart failure and the effect of β-blockade. Am J Cardiol 2004 May 6; 93 (9A): 43B-8B
20. Al-Hesayen A, Azevedo ER, Floras JS, et al. Selective versus nonselective β-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail 2005; 7: 618-23
21. Sackner-Bernstein JD. Practical guidelines to optimize effectiveness of β-blockade in patients postinfarction and in those with chronic heart failure. Am J Cardiol 2004 May 6; 93 (9A): 69B-73B
22. Bruns LA, Canter CE. Should β-blockers be used for the treatment of pediatric patients with chronic heart failure? Pediatr Drugs 2002; 4 (12): 771-8
23. Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916-22
24. Buchhorn R, Hulpke-Wette M, Hilgers R, et al. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PROINFANT Trial. Congestive heart failure in infants treated with propanolol. Int J Cardiol 2001 Jul; 79 (2-3): 167-73
25. Blume ED, Canter CE, Spicer R, et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27: 336-42
26. Rusconi P, Gómez-Marín O, Rossique-González M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004; 23: 832-8
27. Shaddy RE, Boucek MM, Hsu DT, et al. Pediatric Carvedilol study group. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007 Sep 12; 298 (10): 1171-9
28. Azeka E, Franchini Ramires JA, Valler C, et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol therapy. J Am Coll Cardiol 2002; 40 (11): 2034-8
29. Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992 Apr; 13 (2): 72-5
30. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004 Apr 21; 43 (8): 1423-9
31. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94 (11): 2807-16
32. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. US Carvedilol Heart Failure study group. J Card Fail 1997; 3: 173-9
33. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure study group. Circulation 1996; 94 (11): 2800-6
34. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996 Dec; 94 (11): 2793-9
35. Anderson JL, Krause-Steinrauf H, Goldman S, et al. Failure of benefit and early hazard of bucindolol for class IV heart failure. J Card Fail 2003; 9 (4): 266-77
36. Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF and COPERNICUS. J Card Fail 2003; 9 (5): 354-63
37. Fowler MB. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial: Carvedilol in severe heart failure. Am J Cardiol 2004; 93 (9 Suppl. 1): 35-39B
38. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure. J Am Coll Cardiol 2001; 38: 932-8
39. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355: 1873-84
40. Simon MA, Kormos RL, Murali S, et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics and outcomes. Circulation 2005; 112 (9 Suppl.): I32-6
41. Dandel M, Weng Y, Siniawski H, et al. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 2005 Aug 30; 112 (9 Suppl.): I37-45
42. Farrar DJ, Holman WR, McBride LR, et al. Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant 2002 May; 21 (5): 516-21
43. Metra M, Giubbini R, Nodari S, et al. Differential effects of ?-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102: 546-51
44. Sanderson JE, Chan SKW, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999 Nov; 34 (5): 1522-8
45. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001 Jun; 141 (6): 899-907
46. DiLenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999; 33: 1926-34
47. McBride BF, White CM. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. J Clin Pharmacol 2005 Jan; 45 (1): 6-24
48. Talbert RL. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev 2004 Apr; 9 (2): 131-7
49. Dargie HJ. Beta blockers in heart failure. Lancet 2003 Jul 5; 362 (9377): 2-3
50. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40 (7): 1248-58
51. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001; 81: 141-9
52. Gattis WA, O'Connor CM, Leimberger JD, et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003; 91: 169-74
53. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31 (6): 1336-40
54. Kumar A, Choudhary G, Antonio C, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001; 142: 512-5
55. Berger R, Moertl D, Huelsmann M, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 2007 Feb; 9 (2): 202-8
56. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005 Dec; 131 (5): 561-78
57. Green DM, Hyland A, Chung CS, et al. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 1999; 17: 3207-15
58. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191-6
59. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48 (11): 2258-62
60. AAP Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision in individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 2005; 116: 1569-73
61. Rhodes J, Margossian R, Darras B, et al. Carvedilol improves the ventricular function of patients with dilated cardiomyopathy secondary to muscular dystrophy [abstract no. 2442]. Circulation 2006; 114: II-502
62. Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circulation J 2006; 20: 991-4
63. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. Circulation 2005 Dec; 112: 1825-52
64. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary. Eur Heart J 2005; 26: 1115-40
65. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006 Feb; 12 (1): 10-38